155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab)
MICHALEK D, ONENGUT-GUMUSCU S, CHEN W, BRUSKO T, STECK A, GOTTLIEB P, ORAM R, KRISCHER J, PARIKH H, REDONDO M, HEROLD K, RICH S. 155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab). Diabetes 2024, 73 DOI: 10.2337/db24-155-or.Peer-Reviewed Original ResearchGenome-wide analysisTime to progressionInfluence time to progressionPolygenic scoresDrug response genesNon-HLA variantsGenome-wide arrayRandomized phase 2 clinical trialAssociated with time to progressionPhase 2 clinical trialProgression to type 1 diabetesCox proportional hazards regression modelsGenetic variationTn10Proportional hazards regression modelsGenetic modifiersHigh-risk participantsHazards regression modelsLociType 1 diabetesNovel pathwaysTeplizumab groupTeplizumabVitamin DImmune-relevant